A small molecule PKCε inhibitor reduces hyperalgesia induced by paclitaxel or opioid withdrawal
JCI Insight · 2025
DOI: 10.1172/jci.insight.186805 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Adriana Gregory-Flores und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Neuroscience and. Hauptthemen laut MEDLINE: Protein Kinase C-epsilon, Paclitaxel, Hyperalgesia, Analgesics, Opioid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
The enzyme protein kinase C ε (PKCε) plays an important role in pain signaling and represents a promising therapeutic target for the treatment of chronic pain. We designed and generated a small molecule inhibitor of PKCε, CP612, and examined its effect in a rodent model of chemotherapy-induced neuropathic pain produced by paclitaxel, which does not respond well to current therapeutics. In addition, many patients with chronic pain use opiates, which over time can become ineffective, and attempts to discontinue them can increase pain thereby promoting sustained opioid use. Therefore, we also investigated if CP612 alters pain due to opioid withdrawal. We found that CP612 attenuated hyperalgesia produced by paclitaxel, and it both prevented and reversed hyperalgesia induced by opioid withdrawal. It was not self-administered and did not affect morphine self-administration. These findings suggest that inhibition of PKCε is an effective, nonaddictive strategy to treat chemotherapy-induced neuropathic pain, with the added benefit of preventing increases in pain that occur as opioid treatment is discontinued. This latter property could benefit individuals with chronic pain who find it difficult to discontinue opioids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Neuroscience and.
- Department of Neuroscience and the Waggoner Center for Alcohol and Addiction Research, University of Texas at Austin, Austin, Texas, USA.
- Department of Oral and Maxillofacial Surgery, UCSF Pain and Addiction Research Center, and.
- Department of Medicine, Division of Neuroscience, UCSF, San Francisco, California, USA.
- Department of Chemistry, Center for Innovative Drug Discovery, and.
- Voelcker Preclinical Pharmacology Core, Department of Chemistry, University of Texas at San Antonio, San Antonio, Texas, USA.
Förderung
- U.S. Department of Defense
- Cancer Prevention and Research Institute of Texas
Zitieren
APA
Gregory-Flores, A., Bonet, I. J., Desaivre, S., Levine, J. D., McHardy, S. F., de Kraker, H. C., Clanton, N. A., LoCoco, P. M., Russell, N. M., Fleischer, C., Messing, R. O., & Marinelli, M. (2025). A small molecule PKCε inhibitor reduces hyperalgesia induced by paclitaxel or opioid withdrawal. JCI Insight. https://doi.org/10.1172/jci.insight.186805
Vancouver
Gregory-Flores A, Bonet IJ, Desaivre S, Levine JD, McHardy SF, de Kraker HC, et al. A small molecule PKCε inhibitor reduces hyperalgesia induced by paclitaxel or opioid withdrawal. JCI Insight. 2025. doi:10.1172/jci.insight.186805
BibTeX
@article{GregoryFlores2025,
author = {Gregory-Flores, Adriana and Bonet, Ivan Jm and Desaivre, Stève and Levine, Jon D and McHardy, Stanton F and de Kraker, Harmannus C and Clanton, Nicholas A and LoCoco, Peter M and Russell, Nicholas M and Fleischer, Caleb and Messing, Robert O and Marinelli, Michela},
title = {A small molecule PKCε inhibitor reduces hyperalgesia induced by paclitaxel or opioid withdrawal},
journal = {JCI Insight},
year = {2025},
doi = {10.1172/jci.insight.186805}
}
EUVIMED